Take Homes in Breast Cancer

Researchers reported beneficial effects of a supervised exercise intervention on breast cancer outcomes, according to preliminary findings from the OptiTrain trial presented at ESMO Congress.

Breast cancer survivors who participated in a remote personalized exercise program experienced modest improvements in quality of life, according to results from the eMouvoir trial presented at ESMO Congress.

A telephone-based weight loss intervention significantly increased moderate or vigorous physical activity in patients with breast cancer with overweight/obesity, according to a breast cancer weight loss trial presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, discussed the long-term follow-up data of 4-year outcomes from the NATALEE trial.

Trastuzumab deruxtecan, or T-DXd, showed clinical activity in a large population of metastatic HER2-positive breast cancer patients with brain metastases, according to “really impressive” data from DESTINYBreast-12 presented at ESMO Congress.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, talked about an analysis of HERA trial data presented at ESMO Congress.

In a video interview, Nancy Lin, MD, of Dana-Farber Cancer Institute, discussed “interesting updates” from the NATALEE trial presented at ESMO Congress.

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress.